COMPASS Pathways (CMPS) Stifel 2026 Virtual CNS Forum summary

Regulatory and clinical development updates

• Recent data for COMP360 demonstrates potential to redefine durability and rapidity in treatment-resistant depression; rolling NDA submission planned with final data integration expected early Q3 and full submission anticipated by year-end.

• Breakthrough designation may enable priority review, with a potential launch by end of year or early next year, pending regulatory alignment and acceptance.

• Long-term COMP006 data is crucial for labeling, particularly regarding dosing frequency and safety, with no new safety issues observed so far.

Commercial strategy and launch readiness

• Focus is on treatment-resistant depression, a 4 million patient population, with less than 200,000 currently treated using TRD-indicated products due to high patient burden and limited options.

• Key commercial hurdles include ensuring timely federal and state rescheduling post-approval and enabling broad access, targeting 90% of the patient population rescheduled within 30 days of DEA action.

• Efforts underway to educate and prepare sites, ensure REMS compliance, and streamline reimbursement, leveraging established infrastructure from SPRAVATO sites.

Provider and patient adoption dynamics

• Providers are eager for psilocybin availability, with little concern about provider economics; new CPT codes specific to psychedelics are in place to support site reimbursement for the full administration period.

• Early adopters are expected to be high-prescribing SPRAVATO sites with a backlog of interested patients, but most initial patients will be those not currently treated with TRD-indicated products.

• Patient interest is high, and ongoing education will drive referrals and site readiness.